Home Cart 0 Sign in  
X

[ CAS No. 402-67-5 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
3d Animation Molecule Structure of 402-67-5
Chemical Structure| 402-67-5
Chemical Structure| 402-67-5
Structure of 402-67-5 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 402-67-5 ]

Related Doc. of [ 402-67-5 ]

Alternatived Products of [ 402-67-5 ]

Product Details of [ 402-67-5 ]

CAS No. :402-67-5 MDL No. :MFCD00007196
Formula : C6H4FNO2 Boiling Point : -
Linear Structure Formula :- InChI Key :WMASLRCNNKMRFP-UHFFFAOYSA-N
M.W : 141.10 Pubchem ID :9823
Synonyms :

Calculated chemistry of [ 402-67-5 ]

Physicochemical Properties

Num. heavy atoms : 10
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.0
Num. rotatable bonds : 1
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 35.22
TPSA : 45.82 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.81 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.39
Log Po/w (XLOGP3) : 1.9
Log Po/w (WLOGP) : 2.15
Log Po/w (MLOGP) : 1.29
Log Po/w (SILICOS-IT) : 0.11
Consensus Log Po/w : 1.37

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.29
Solubility : 0.724 mg/ml ; 0.00513 mol/l
Class : Soluble
Log S (Ali) : -2.49
Solubility : 0.462 mg/ml ; 0.00327 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.03
Solubility : 1.31 mg/ml ; 0.00931 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 2.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.68

Safety of [ 402-67-5 ]

Signal Word:Danger Class:6.1
Precautionary Statements:P210-P261-P280-P301+P310-P311 UN#:2810
Hazard Statements:H227-H301+H311+H331-H373 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 402-67-5 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 402-67-5 ]
  • Downstream synthetic route of [ 402-67-5 ]

[ 402-67-5 ] Synthesis Path-Upstream   1~28

  • 1
  • [ 288-13-1 ]
  • [ 402-67-5 ]
  • [ 25688-18-0 ]
YieldReaction ConditionsOperation in experiment
71% With caesium carbonate In 1-methyl-pyrrolidin-2-one at 100℃; for 17 h; A mixture of 3-fluoronitrobenzene (1.0 g, 7.1 mmol), pyrazole (0.58 g, 8.5 mmol), and cesium carbonate (2.8 g, 8.5 mmol) in 4 mL of N-methylpyrrolidinone was heated to 100°C for 17 h. After cooling to rt, the mixture was diluted with water (75 mL) and extracted with ethyl acetate (3 x 75 mL) and the combined extracts were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford 1.7 g (71 percent) of 110A as a dark red oil. LCMS (M+H+) = 190.1. HPLC Ret. time: 2.42 min.
Reference: [1] Patent: WO2003/90912, 2003, A1, . Location in patent: Page/Page column 85-86
[2] Australian Journal of Chemistry, 1993, vol. 46, # 4, p. 417 - 425
  • 2
  • [ 110-85-0 ]
  • [ 402-67-5 ]
  • [ 54054-85-2 ]
YieldReaction ConditionsOperation in experiment
72% With potassium carbonate In dimethyl sulfoxide at 100℃; for 24 h; A mixture of piperazine (12 g, 138 mmol), 1-fluoro-3-nitrobenzene (4 ml, 34 mmol) and potassium carbonate (9.60 g, 69 mmol) in DMSO (40 mL) is heated at 100°C for 24 h. The reaction is quenched with H2O (60 mL) and extracted with Et2O (3 x 20 mL). The organic layer is washed with brine (20 mL) and dried over Na2SO4 and concentrated in vacuo. The residue is chromatographied on silica gel eluting with CH2Cl2/ MeOH (94 / 6) to yield the title compound (5.15 g, 72percent) as an orange solid. This solid was dissolved in CH2Cl2 and Boc2O (6 g, 130 mmol) was added. The mixture was stirred overnight. The solvent was evaporated and the residual solid was crystallized in heptane (6.80 g, 93percent, mp 86°C). 1H NMR (200 MHz, CDCl3) δ 1.49 (s, 9 H), 3.22-3.27 (m, 4 H), 3.58-3.63 (m, 4 H), 7.16-7.71 (m, 4 H).
71% at 70℃; for 120 h; A suspension of 3-fluoronitrobenzene (23 ml ; 0.21 mol) and piperazine (55.5 G ; 0.64 mol) in anhydrous NMP (30 ml) was heated to 70°C for five days. The cooled mixture was diluted with water (250 ML) and extracted with dichloromethane. The combined extracts were dried over magnesium sulphate and concentrated under reduced pressure. The residue was purified by column-chromatography on silica gel eluting subsequently with mixtures of ethyl acetate and methanol (4: 1 v/v) and (1: 1 V/V) to leave the desired product as oily crystals (30. 7 G ; 71percent).
65% at 100℃; for 60 h; 1-(3-nitrophenyl)piperazine
28.4 g (0.33 mol, 5.5 eq) of piperazine is dissolved in 50 ml of DMSO. 6.4 ml (60 mmol) of 2-fluoronitrobenzene is added.
The mixture is heated at 100° C. for 60 hours.
After cooling, the reaction mixture is transferred into 530 ml of water.
The precipitate formed is filtered and the filtrate extracted with Et2O.
After drying on MgSO4 and concentration under vacuum, the crude product is purified by column chromatography (eluent CH2Cl2/MeOH 9:1) to produce 8.04 g of the expected compound in the form of an orange oil which crystallizes at room temperature (yield: 65percent).
C10H13N3O2
M=207.26 g/mol
1H NMR (CDCl3) δ (ppm): 7.70 (t, Jm=2 Hz, 1H, CH(2')); 7.64 (ddd, Jo=8 Hz, Jm=2 Hz, Jm=0.6 Hz, 1H, CH(4')); 7.36 (t, Jo=8 Hz, 1H, CH(5')), 7.17 (ddd, Jo=8 Hz, Jm=2 Hz, Jm=0.6 Hz, 1H, CH(6')); 3.30-3.18 (m, 4H, CH2(3), CH2(5)); 3.09-2.97 (m, 4H, CH2(2), CH2(6)),
65% at 100℃; for 60 h; EXAMPLE 1
1-(3-nitrophenyl)piperazine
28.4 g (0.33 mol, 5.5 eq) of piperazine were dissolved in 50 ml of DMSO, then 6.4 ml (60 mmol) of 3-fluoronitrobenzene were added.
The mixture was heated at 100° C. for 60 h.
After cooling, the reaction medium was poured in 530 ml of water.
The resulting precipitate was filtered and the filtrate extracted with Et2O.
After drying on MgSO4 and vacuum concentration, the crude product was purified by column chromatography (eluent: CH2Cl2/MeOH 9:1) to give 8.04 g of the expected compound in the form of an orange oil which crystallized at room temperature (yield: 65percent).
1H NMR (CDCl3) δ (ppm): 7.70 (t, Jm=2 Hz, 1H, CH(2')); 7.64 (ddd, Jo=8 Hz, Jm=2 Hz, Jm=0.6 Hz, 1H, CH(4')); 7.36 (t, Jo=8 Hz, 1H, CH(5')), 7.17 (ddd, Jo=8 Hz, Jm=2 Hz, Jm=0.6 Hz, 1H, CH(6')); 3.30-3.18 (m, 4H, CH2(3), CH2(5)); 3.09-2.97 (m, 4H, CH2(2), CH2(6)).

Reference: [1] Patent: EP1683790, 2006, A1, . Location in patent: Page/Page column 7; 12
[2] Patent: US2003/55055, 2003, A1,
[3] Patent: WO2004/89912, 2004, A1, . Location in patent: Page 26
[4] Patent: US2004/58933, 2004, A1, . Location in patent: Page/Page column 37
[5] Patent: US2005/267126, 2005, A1, . Location in patent: Page/Page column 9
[6] Bioorganic and Medicinal Chemistry Letters, 2004, vol. 14, # 10, p. 2567 - 2570
[7] Patent: WO2006/111517, 2006, A1, . Location in patent: Page/Page column 15
  • 3
  • [ 402-67-5 ]
  • [ 1526-17-6 ]
  • [ 403-19-0 ]
Reference: [1] Journal of Organic Chemistry, 1990, vol. 55, # 17, p. 4979 - 4981
  • 4
  • [ 402-67-5 ]
  • [ 403-19-0 ]
Reference: [1] Journal of Organic Chemistry, 1998, vol. 63, # 13, p. 4199 - 4208
  • 5
  • [ 402-67-5 ]
  • [ 1526-17-6 ]
  • [ 403-19-0 ]
Reference: [1] Journal of Organic Chemistry, 1990, vol. 55, # 17, p. 4979 - 4981
  • 6
  • [ 98-95-3 ]
  • [ 402-67-5 ]
  • [ 19064-24-5 ]
  • [ 350-46-9 ]
  • [ 1493-27-2 ]
Reference: [1] Journal of Fluorine Chemistry, 1981, vol. 18, p. 363 - 374
[2] Journal of Fluorine Chemistry, 1981, vol. 18, p. 363 - 374
[3] Journal of Fluorine Chemistry, 1981, vol. 18, p. 363 - 374
  • 7
  • [ 98-95-3 ]
  • [ 402-67-5 ]
  • [ 19064-24-5 ]
  • [ 446-35-5 ]
  • [ 2265-94-3 ]
  • [ 350-46-9 ]
  • [ 1493-27-2 ]
Reference: [1] Journal of Fluorine Chemistry, 1981, vol. 18, p. 363 - 374
  • 8
  • [ 98-95-3 ]
  • [ 402-67-5 ]
  • [ 446-35-5 ]
  • [ 350-46-9 ]
  • [ 1493-27-2 ]
Reference: [1] Journal of Fluorine Chemistry, 1981, vol. 18, p. 363 - 374
  • 9
  • [ 98-95-3 ]
  • [ 402-67-5 ]
  • [ 19064-24-5 ]
  • [ 446-35-5 ]
  • [ 2265-94-3 ]
  • [ 350-46-9 ]
  • [ 1493-27-2 ]
Reference: [1] Journal of Fluorine Chemistry, 1981, vol. 18, p. 363 - 374
  • 10
  • [ 402-67-5 ]
  • [ 364-78-3 ]
  • [ 17809-36-8 ]
  • [ 369-35-7 ]
Reference: [1] Journal of Organic Chemistry, 1996, vol. 61, # 2, p. 442 - 443
[2] Journal of Organic Chemistry, 1996, vol. 61, # 9, p. 2934 - 2935
[3] Journal of the Chemical Society - Perkin Transactions 1, 1999, # 11, p. 1437 - 1444
  • 11
  • [ 98-95-3 ]
  • [ 402-67-5 ]
  • [ 369-34-6 ]
  • [ 364-74-9 ]
  • [ 350-46-9 ]
  • [ 1493-27-2 ]
YieldReaction ConditionsOperation in experiment
0.05 mmol at 0 - 25℃; Cooling with ice General procedure: A FEP or PFA reactor equipped with a Teflon-lined magnetic stir bar and connected to a gas-washing bottle was charged with substituted benzene (0.95–1.10 mmol), 1,1,1,3,3-pentafluorobutane (1–2 mL per mmol of C6H5R), and BF3 · Et2O (1.3–1.5 mmol per mmol of C6H5R). The mixture was stirred for 10–15 min at 0–5°C (ice bath), and XeF2 (1.2–1.3 mmol per mmol of C6H5R) was added in portions. After addition of each portion, the mixture was stirred for 3–5 min at 22–25°C and cooled again. When the addition was complete the dark solution was stirred for 15–30 min at 22–25°C, 10percent aqueous KHCO3 was added, and the upper organic layer was separated, passed through a short column charged with silica gel (40–60 μm), and dried over MgSO4. The solution was analyzed by 19F NMR and GC/MS. The main products are given in table, and the others are listed below (GC/MS data).
Reference: [1] Russian Journal of Organic Chemistry, 2016, vol. 52, # 10, p. 1400 - 1407[2] Zh. Org. Khim., 2016, vol. 52, # 10, p. 1412 - 1419,8
  • 12
  • [ 402-67-5 ]
  • [ 21397-07-9 ]
YieldReaction ConditionsOperation in experiment
79.8% With hexachloroethane; lithium tert-butoxide In N,N-dimethyl-formamide at 60℃; for 4 h; Inert atmosphere A solution of 1-fluoro-3-nitrobenzene (1.41g, 10mmol), t-BuOLi (2.00g, 25mmol) and C2Cl6 (4.73g, 20 mmol) in 15ml dry DMF was stirred for 4h at 60°C under N2 atmosphere. Ethyl acetate was added and the resulting organic solution was washed by 1M HCl, saturated NaHCO3 and brine successively. The solvent was removed under reduced pressure and the residue was purified on column chromatography (eluted by 0.5percent ethyl acetate in petroleum ether) to obtain 6 as a colorless oil. Yield: 79.8percent, 1H NMR (400 MHz, CDCl3) δ 7.77–7.69 (m, 1H, Ph-H), 7.48–7.41 (m, 2H, Ph-H).
9.2% With hydrogenchloride; N-chloro-succinimide In tetrahydrofuran; ethyl acetate a
2-chloro-3-fluoronitrobenzene
To a -78° C. solution of 3-fluoronitrobenzene (2 g, 14.2 mmol) in THF (30 mL) was added N-chlorosuccinimide (5.69 g, 42.6 mmol) in THF (20 mL), NaHMDS (1 M in THF, 28.4 mL, 28.4 mmol) was then added dropwise to maintain an internal temperature below -75° C.
The resulting mixture was stirred for 30 min at -78° C.
Then it was partitioned between 5percent of HCl and ethyl acetate.
The combined organic layer is dried over MgSO4 and filtered.
The solvent was evaporated and chromatography of the resulting solid on silica gel (20percent Ethyl acetate Hexane) gave the desired product(231 mg, 9.2percent). EI-MS m/z 176.5 (M+).
9.6% With N-Bromosuccinimide In tetrahydrofuran; ethyl acetate a
2-chloro-3-fluoronitrobenzene
To a -78° C. solution of 3-fluoronitrobenzene (2 g, 14.2 mmol) in THF (30 mL) was added N-bromosuccinimide (7.58 g, 42.6 mmol) in THF (20 mL), NaHMDS (1 M in THF, 28.4 mL, 28.4 mmol) was then added dropwise to maintain an internal temperature below -75° C.
The resulting mixture was stirred for 30 min at -784C.
Then it was partitioned between 5percent of HCL and ethyl acetate..
The combined organic layer is dried over MgSO4 and filtered.
The solvent was evaporated and chromatography of the resulting solid on silica gel (20percent Ethyl acetate/Hexane) gave the desired product (300 mg, 9.6percent). EI-MS m/z 221 (M+).
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2017, vol. 27, # 15, p. 3365 - 3369
[2] Journal of Organic Chemistry, 2011, vol. 76, # 9, p. 3416 - 3437
[3] Patent: US6500863, 2002, B1,
[4] Patent: US6500863, 2002, B1,
  • 13
  • [ 402-67-5 ]
  • [ 59255-94-6 ]
Reference: [1] Organic Letters, 2009, vol. 11, # 2, p. 421 - 423
[2] Journal of Organic Chemistry, 2009, vol. 74, # 21, p. 8309 - 8313
[3] Journal of Organic Chemistry, 2011, vol. 76, # 9, p. 3416 - 3437
  • 14
  • [ 402-67-5 ]
  • [ 364-53-4 ]
Reference: [1] Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1980, p. 982 - 994
[2] Tetrahedron Letters, 2000, vol. 41, # 22, p. 4277 - 4279
[3] Journal of the Chemical Society, 1953, p. 3042
  • 15
  • [ 402-67-5 ]
  • [ 399-96-2 ]
Reference: [1] Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1964, vol. 259, p. 3030 - 3032
[2] Bulletin de la Societe Chimique de France, 1966, p. 1848 - 1858
  • 16
  • [ 402-67-5 ]
  • [ 18645-88-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2015, vol. 58, # 2, p. 588 - 597
  • 17
  • [ 402-67-5 ]
  • [ 364-78-3 ]
  • [ 17809-36-8 ]
  • [ 369-35-7 ]
Reference: [1] Journal of Organic Chemistry, 1996, vol. 61, # 2, p. 442 - 443
[2] Journal of Organic Chemistry, 1996, vol. 61, # 9, p. 2934 - 2935
[3] Journal of the Chemical Society - Perkin Transactions 1, 1999, # 11, p. 1437 - 1444
  • 18
  • [ 402-67-5 ]
  • [ 17809-36-8 ]
Reference: [1] Journal of Medicinal Chemistry, 2015, vol. 58, # 2, p. 588 - 597
  • 19
  • [ 402-67-5 ]
  • [ 369-35-7 ]
Reference: [1] Journal of Organic Chemistry, 1998, vol. 63, # 15, p. 4878 - 4888
[2] Journal of Organic Chemistry, 1986, vol. 51, # 25, p. 5039 - 5040
[3] Journal of Heterocyclic Chemistry, 1994, vol. 31, # 6, p. 1513 - 1520
  • 20
  • [ 402-67-5 ]
  • [ 364-78-3 ]
  • [ 17809-36-8 ]
  • [ 369-35-7 ]
Reference: [1] Journal of Organic Chemistry, 1996, vol. 61, # 2, p. 442 - 443
[2] Journal of Organic Chemistry, 1996, vol. 61, # 9, p. 2934 - 2935
[3] Journal of the Chemical Society - Perkin Transactions 1, 1999, # 11, p. 1437 - 1444
  • 21
  • [ 402-67-5 ]
  • [ 21397-08-0 ]
Reference: [1] Journal of Organic Chemistry, 2011, vol. 76, # 9, p. 3416 - 3437
  • 22
  • [ 402-67-5 ]
  • [ 27126-93-8 ]
  • [ 34470-17-2 ]
Reference: [1] Journal of the American Chemical Society, 1986, vol. 108, # 18, p. 5453 - 5459
  • 23
  • [ 402-67-5 ]
  • [ 111721-75-6 ]
Reference: [1] Journal of Organic Chemistry, 2011, vol. 76, # 9, p. 3416 - 3437
  • 24
  • [ 402-67-5 ]
  • [ 148546-99-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 26, p. 8261 - 8269
[2] Patent: WO2004/101533, 2004, A1, . Location in patent: Page 95
[3] Patent: WO2014/125410, 2014, A1,
[4] Journal of Medicinal Chemistry, 2017, vol. 60, # 12, p. 5099 - 5119
  • 25
  • [ 402-67-5 ]
  • [ 88088-95-3 ]
  • [ 157701-72-9 ]
Reference: [1] Tetrahedron Letters, 1996, vol. 37, # 3, p. 347 - 350
  • 26
  • [ 402-67-5 ]
  • [ 149524-42-5 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 18, p. 5266 - 5269
  • 27
  • [ 402-67-5 ]
  • [ 159724-40-0 ]
Reference: [1] Journal of Medicinal Chemistry, 2006, vol. 49, # 7, p. 2253 - 2261
[2] Journal of Medicinal Chemistry, 2005, vol. 48, # 26, p. 8261 - 8269
[3] Patent: WO2004/101533, 2004, A1, . Location in patent: Page 92
[4] Patent: WO2015/38417, 2015, A1,
[5] Patent: JP2017/179131, 2017, A,
[6] Patent: US6589950, 2003, B1,
[7] Patent: WO2003/90912, 2003, A1,
  • 28
  • [ 402-67-5 ]
  • [ 626248-56-4 ]
Reference: [1] Patent: WO2014/152768, 2014, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 402-67-5 ]

Fluorinated Building Blocks

Chemical Structure| 2369-12-2

[ 2369-12-2 ]

3-Fluoro-5-nitroaniline

Similarity: 0.96

Chemical Structure| 369-34-6

[ 369-34-6 ]

3,4-Difluoronitrobenzene

Similarity: 0.96

Chemical Structure| 2369-11-1

[ 2369-11-1 ]

5-Fluoro-2-nitroaniline

Similarity: 0.92

Chemical Structure| 364-78-3

[ 364-78-3 ]

4-Fluoro-2-nitroaniline

Similarity: 0.92

Chemical Structure| 369-35-7

[ 369-35-7 ]

2-Fluoro-4-nitroaniline

Similarity: 0.92

Aryls

Chemical Structure| 2369-12-2

[ 2369-12-2 ]

3-Fluoro-5-nitroaniline

Similarity: 0.96

Chemical Structure| 369-34-6

[ 369-34-6 ]

3,4-Difluoronitrobenzene

Similarity: 0.96

Chemical Structure| 2369-11-1

[ 2369-11-1 ]

5-Fluoro-2-nitroaniline

Similarity: 0.92

Chemical Structure| 364-78-3

[ 364-78-3 ]

4-Fluoro-2-nitroaniline

Similarity: 0.92

Chemical Structure| 369-35-7

[ 369-35-7 ]

2-Fluoro-4-nitroaniline

Similarity: 0.92

Nitroes

Chemical Structure| 2369-12-2

[ 2369-12-2 ]

3-Fluoro-5-nitroaniline

Similarity: 0.96

Chemical Structure| 369-34-6

[ 369-34-6 ]

3,4-Difluoronitrobenzene

Similarity: 0.96

Chemical Structure| 2369-11-1

[ 2369-11-1 ]

5-Fluoro-2-nitroaniline

Similarity: 0.92

Chemical Structure| 364-78-3

[ 364-78-3 ]

4-Fluoro-2-nitroaniline

Similarity: 0.92

Chemical Structure| 369-35-7

[ 369-35-7 ]

2-Fluoro-4-nitroaniline

Similarity: 0.92